London-based Clinigen Group pc will have full rights to Proleukin (aldesleukin, human recombinant interleukin-2). This morning, the U.K.-based pharmaceutical and services company struck a deal with Novartis to acquire the U.S. rights to the metastatic renal cell carcinoma treatment.
Clinigen signed an agreement with the Swiss pharma giant to acquire the U.S. rights for up to $210 million in cash. The payment consisted of a $120 million upfront payment, a deferred payment of $60 million and future sales-related milestones that could total $30 million. Clinigen already owns the rights to Proleukin outside the US, which it acquired in July 2018.
Shaun Chilton, group chief executive officer at Clinigen, said the U.S. rights to Proleukin will be significant for the whole of the company, not just its Commercial Medicines division. Chilton noted that the acquisition will allow the Clinigen Group to expand its footprint in the U.S. market.
In its announcement, Clinigen said Proleukin further diversifies its Commercial Medicines portfolio of niche hospital-only and critical care products. That division also has the U.S. rights to other assets, including Foscavir, Ethyol and Totect. Commercial rights for those three drugs have been licensed to Pfizer (Foscavir) and Cumberland Pharmaceuticals (Ethyol and Totect), Clinigen said.
Proleukin generated $60 million in revenue in the United States for the year leading up to June 30, 2018, Clinigen said, citing data from IQVIA. The company said gross profit margin is expected to be similar to other specialty medicines within its Commercial Medicines division.